[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2010DE02164A - - Google Patents

Download PDF

Info

Publication number
IN2010DE02164A
IN2010DE02164A IN2164DE2010A IN2010DE02164A IN 2010DE02164 A IN2010DE02164 A IN 2010DE02164A IN 2164DE2010 A IN2164DE2010 A IN 2164DE2010A IN 2010DE02164 A IN2010DE02164 A IN 2010DE02164A
Authority
IN
India
Prior art keywords
formula
dpp
diabetes
inhibitors
synthesis
Prior art date
Application number
Other languages
English (en)
Inventor
Rajesh Jain
Jagadeeshwar R Rao
Siripragada Mahender Rao
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Priority to PCT/IN2011/000621 priority Critical patent/WO2012035549A2/fr
Priority to IN2164DE2010 priority patent/IN2010DE02164A/en
Priority to ARP110103328A priority patent/AR082971A1/es
Publication of IN2010DE02164A publication Critical patent/IN2010DE02164A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2164DE2010 2010-09-13 2011-09-12 IN2010DE02164A (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IN2011/000621 WO2012035549A2 (fr) 2010-09-13 2011-09-12 Procédé amélioré pour la synthèse de dérivés d'acides bêta-aminés
IN2164DE2010 IN2010DE02164A (fr) 2010-09-13 2011-09-12
ARP110103328A AR082971A1 (es) 2010-09-13 2011-09-13 PROCESO PARA LA SINTESIS DE DERIVADOS DE b-AMINOACIDO

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2164DE2010 IN2010DE02164A (fr) 2010-09-13 2011-09-12

Publications (1)

Publication Number Publication Date
IN2010DE02164A true IN2010DE02164A (fr) 2015-07-24

Family

ID=44898127

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2164DE2010 IN2010DE02164A (fr) 2010-09-13 2011-09-12

Country Status (3)

Country Link
AR (1) AR082971A1 (fr)
IN (1) IN2010DE02164A (fr)
WO (1) WO2012035549A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145333A1 (fr) 2014-03-26 2015-10-01 Sun Pharmaceutical Industries Limited Procédé de préparation de sitagliptine et son intermédiaire

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JP4530852B2 (ja) 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
PL216527B1 (pl) 2002-10-18 2014-04-30 Merck & Co Inc Związki ß-aminoheterocykliczne i kompozycja farmaceutyczna
CA2504735C (fr) 2002-11-07 2009-06-23 Merck & Co., Inc. Derives de phenylalanine utilises comme inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete
CA2508947A1 (fr) * 2002-12-20 2004-07-15 Merck & Co., Inc. Derives de 3-amino-4-phenylbutanoique acide utilises en tant qu'inhibiteurs de dipeptidyl peptidase pour le traitement ou la prevention du diabete
AR043515A1 (es) 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
DE602004018503D1 (de) 2003-07-31 2009-01-29 Merck & Co Inc Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
AU2004286857A1 (en) 2003-11-04 2005-05-19 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP2007538079A (ja) 2004-05-18 2007-12-27 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−iv阻害剤としてのシクロヘキシルアラニン誘導体
EP1598341A1 (fr) 2004-05-21 2005-11-23 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Inhibiteurs de DPP-IV
EP1604662A1 (fr) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2
EP1604989A1 (fr) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Inhibiteurs de DPP-IV
GB0413389D0 (en) 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
JP4963671B2 (ja) 2004-06-21 2012-06-27 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−iv阻害剤としてのアミノシクロヘキサン
ATE473742T1 (de) 2004-08-23 2010-07-15 Merck Sharp & Dohme Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
CN101031300A (zh) 2004-10-01 2007-09-05 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶-ⅳ抑制剂的氨基哌啶化合物
AR052879A1 (es) 2005-01-24 2007-04-11 Merck & Co Inc Procedimiento para preparar derivados de beta aminoacidos quirales por hidrogenacion asimetrica
EP1702916A1 (fr) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH Inhibiteurs de DPP-IV
US20090124601A1 (en) * 2005-03-29 2009-05-14 Song Zhiguo J Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor
EP1943215A2 (fr) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Inhibiteurs à base d amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
WO2007054577A1 (fr) 2005-11-14 2007-05-18 Probiodrug Ag Derives de pyrrolidine a fusion de cyclopropyle, en tant qu'inhibiteurs de dipeptidyle peptidase iv (dp iv)
WO2007063928A1 (fr) 2005-11-30 2007-06-07 Toray Industries, Inc. Nouveau derive non cyclique d’amine carboxamide et sel de celui-ci
AP2010005364A0 (en) * 2008-01-24 2010-08-31 Panacea Biotec Ltd Novel heterocyclic compounds.
EP2223923A1 (fr) * 2009-02-25 2010-09-01 Esteve Química, S.A. Procédé pour la préparation d'un dérivé d'acide aminé chiral bêta et intermédiaires correspondants

Also Published As

Publication number Publication date
AR082971A1 (es) 2013-01-23
WO2012035549A3 (fr) 2012-10-11
WO2012035549A2 (fr) 2012-03-22

Similar Documents

Publication Publication Date Title
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY155517A (en) Heterocyclic derivatives
NZ601121A (en) 5-alkynyl-pyrimidines
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MX339252B (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
EA201390643A1 (ru) Кристаллические формы гидрохлорида (4a-r,9a-s)-1-(1h-бензоимидазол-5-карбонил-2,3,4,4a,9,9a-гексагидро-1h-индено[2,1-b]пиридин-6-карбонитрила и их применение в качестве ингибиторов hsd 1
EA201270302A1 (ru) Безводные формы производных пиридина
MX2012000178A (es) 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives